Sandu Pharmaceuticals Ltd — Important, 07-02-2026: Company Update

Sandu Pharmaceuticals' board has approved its financial results for the quarter and nine-month period ending December 31, 2025. For the quarter, total income from operations stood at 18.77 Cr, with a net profit of 0.98 Cr and earnings per share of 1.01. The nine-month period saw total income at 53.16 Cr, generating a net profit of 1.72 Cr and EPS of 1.78. This update provides crucial insights into the company's recent operational and profitability performance for investors.

The company has also informed shareholders about a special window for the transfer and dematerialisation of physical securities. This window, open from February 5, 2026, to February 4, 2027, allows conversion of physical shares to demat form, including previously rejected requests. Transferred securities will be subject to a one-year lock-in period from the date of transfer registration, impacting immediate liquidity. Shareholders with physical shares should contact the RTA.